Upregulation of PD-L1 and PD-L2 in neck node metastases of head and neck squamous cell carcinoma

被引:41
|
作者
Moratin, Julius [1 ]
Metzger, Karl [1 ]
Safaltin, Ayse [1 ]
Herpel, Esther [2 ,3 ]
Hoffmann, Juergen [1 ]
Freier, Kolja [1 ,4 ]
Hess, Jochen [5 ,6 ]
Horn, Dominik [1 ,4 ]
机构
[1] Heidelberg Univ Hosp, Dept Oral & Craniomaxillofacial Surg, Neuenheimer Feld 400, D-69120 Heidelberg, Germany
[2] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany
[3] Natl Ctr Tumor Dis NCT, Tissue Bank, Heidelberg, Germany
[4] Saarland Univ Hosp, Dept Oral & Maxillofacial Surg, Homburg, Germany
[5] Heidelberg Univ Hosp, Dept Otorhinolaryngol Head & Neck Surg, Heidelberg, Germany
[6] German Canc Res Ctr, Res Grp Mol Mech Head & Neck Tumors, Heidelberg, Germany
关键词
HNSCC; immune checkpoint; lymph node metastases; PD-L1; PD-L2; EXPRESSION; RECURRENT; PEMBROLIZUMAB; PATHWAY; RECOGNITION; PROGRESSION; DISSECTION; RESISTANCE; RELEVANCE; NIVOLUMAB;
D O I
10.1002/hed.25713
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background This study aimed on evaluating the expression levels of the immune checkpoint proteins, PD-L1 and PD-L2, in tissue specimens of 175 oral squamous cell carcinomas (OSCC) and 33 corresponding lymph node metastases (LNM). Methods Tissue microarrays of primary OSCC and matched LNM were investigated via immunohistochemistry regarding PD-L1/PD-L2 expression. Results were compared for primary tumors and corresponding metastases and correlated with clinicopathological data. Results PD-L1 expression in cancer cells correlated significantly with tumor size, and the presence of regional metastases (P < 0.01). PD-L1 expression was significantly higher in metastases as compared to primary OSCC (P < 0.05). Overall survival was significantly worse in patients with higher levels of PD-L1 and PD-L2 score (P < 0.05). Conclusions This is the first publication to compare PD-L1 and PD-L2 expression in primary OSCC and matched LNM. The results indicate that anti-PD-1 therapy may be of therapeutic use even in early stage OSCC to prevent further progression.
引用
收藏
页码:2484 / 2491
页数:8
相关论文
共 50 条
  • [41] Differential Expression of PD-L1 during Cell Cycle Progression of Head and Neck Squamous Cell Carcinoma
    Schulz, Daniela
    Wetzel, Martin
    Eichberger, Jonas
    Piendl, Gerhard
    Brockhoff, Gero
    Wege, Anja K.
    Reichert, Torsten E.
    Ettl, Tobias
    Bauer, Richard J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (23)
  • [42] Association of PD-1, PD-L1 and PD-L2 expression with clinicopathological factors in tongue squamous cell carcinoma
    Tsuchihashi, Kei
    Nakatsugawa, Munehide
    Asanuma, Hiroko
    Miyazaki, Akihiro
    Torigoe, Toshihiko
    CANCER SCIENCE, 2018, 109 : 498 - 498
  • [43] The PD-1/PD-L1 axis and clinical outcomes in head and neck squamous cell carcinomas
    Trivedi, Sumita
    Seethala, Raja R.
    Ferris, Robert L.
    CANCER RESEARCH, 2016, 76
  • [44] PD-L1 promotes head and neck squamous cell carcinoma cell growth through mTOR signaling
    Zheng, Anyuan
    Li, Fen
    Chen, Fuhai
    Zuo, Jingjing
    Wang, Lei
    Wang, Yongping
    Chen, Shiming
    Xiao, Bokui
    Tao, Zezhang
    ONCOLOGY REPORTS, 2019, 41 (05) : 2833 - 2843
  • [45] PD-L1 Detection and Assay Performance in Squamous Cell Carcinoma of the Head and Neck Using PD-L1 IHC 28-8 pharmDx
    Alvarez, S.
    Chan, J.
    William, J.
    Felten, C.
    Hanks, D. A.
    Northrup, A.
    Jaiswal, D.
    Jansson, M.
    Phillips, T.
    Segal, A.
    Satnick, I.
    McDonald, H.
    Little, H.
    Pierce, C.
    Wynne, B.
    Carnahan, J.
    Reddy, S. Y.
    Inzunza, H. D.
    Oroudjev, E.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
    Tran, Linda
    Allen, Clint T.
    Xiao, Roy
    Moore, Ellen
    Davis, Ruth
    Park, So-Jin
    Spielbauer, Katie
    Van Waes, Carter
    Schmitt, Nicole C.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (12) : 1141 - 1151
  • [47] Comparison of PD-L1 immunohistochemical assays in head and neck carcinoma
    Jeong, J.
    Jo, U.
    Cho, K.
    Song, J. S.
    VIRCHOWS ARCHIV, 2022, 481 (SUPPL 1) : S70 - S71
  • [48] The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma
    Liu, Wei
    Chen, Shengkai
    Yang, Wenbin
    ORAL ONCOLOGY, 2018, 87 : 199 - 200
  • [49] Choice of PD-L1 Scoring and Cutoff in Head and Neck Squamous Cell Carcinoma (HNSCC) Trials of Pembrolizumab
    Emancipator, Kenneth
    Juco, Jonathan
    Huang, Lingkang
    Lunceford, Jared
    Cheng, Jonathan
    Ge, Joy
    Gause, Christine
    Swaby, Ramona
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1192 - 1193
  • [50] Digital Pathology Applications for PD-L1 Scoring in Head and Neck Squamous Cell Carcinoma: A Challenging Series
    Canini, Valentina
    Eccher, Albino
    d'Amati, Giulia
    Fusco, Nicola
    Maffini, Fausto
    Lepanto, Daniela
    Martini, Maurizio
    Cazzaniga, Giorgio
    Paliogiannis, Panagiotis
    Lobrano, Renato
    L'Imperio, Vincenzo
    Pagni, Fabio
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)